KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures (2016 - 2018)

Teva Pharmaceutical Industries (TEVA) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $1.6 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2018, changed N/A, and an annual FY2018 reading of $1.6 million, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $1.6 million for Q4 2018 at Teva Pharmaceutical Industries, up from $830000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q4 2018 and bottomed at -$1.1 million in Q4 2015.
  • Average Gains from Sales and Divestitures over 4 years is $625500.0, with a median of $988000.0 recorded in 2014.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 197.03% in 2015, then soared 174.64% in 2016.
  • Year by year, Gains from Sales and Divestitures stood at $1.1 million in 2014, then tumbled by 197.03% to -$1.1 million in 2015, then skyrocketed by 174.64% to $830000.0 in 2016, then soared by 97.35% to $1.6 million in 2018.
  • Business Quant data shows Gains from Sales and Divestitures for TEVA at $1.6 million in Q4 2018, $830000.0 in Q4 2016, and -$1.1 million in Q4 2015.